Genmab A (GMAB) Income from Continuing Operations (2018 - 2026)

Genmab A (GMAB) has reported Income from Continuing Operations for 9 consecutive years, with $287.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income from Continuing Operations fell 64.26% year-over-year to $287.0 million; the trailing twelve-month figure through Jun 2026 stood at $2.3 billion (up 12.6% YoY), and the FY2025 full-year result was $963.0 million, down 28.59% from the prior year.
• Income from Continuing Operations advanced to $287.0 million in Q2 2026 per GMAB's latest filing, from $75.0 million in the prior quarter.
• Across five years, Income from Continuing Operations topped out at $2.7 billion in Q3 2023 and bottomed at -$3.8 billion in Q4 2023.
• Historically, Income from Continuing Operations has averaged $260.4 million across 5 years, with a median of $253.7 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations tumbled 70.06% in 2024, then soared 303.27% in 2025.
• Over 5 years, Income from Continuing Operations stood at $253.7 million in 2022, then tumbled by 1602.73% to -$3.8 billion in 2023, then soared by 121.22% to $809.0 million in 2024, then surged by 42.03% to $1.1 billion in 2025, then tumbled by 75.02% to $287.0 million in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered $287.0 million, $75.0 million, and $1.1 billion for Q2 2026, Q1 2026, and Q3 2025 respectively.